Literature DB >> 12227130

Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review.

Bernd Richter1, Gudrun Neises, Christine Clar.   

Abstract

This systematic review highlights the uncertainty about the safety and efficacy of glucocorticoid withdrawal in many chronic diseases, elucidating the need for further research in this area. The problem of glucocorticoid withdrawal seems to be good example for wide variation in physicians' approaches to weaning patients off glucocorticoids. This practice variation appears justified, given the well known extraordinary array of individual reactions to systemic glucocorticoid therapy [44], the obligation to individualize treatment, and scientific uncertainty. Moreover, only sparse information concerning health-related quality of life, well-being and symptoms, and socioeconomic sequelae after glucocorticoid withdrawal is available from published randomized trials. In conclusion, clinicians and patients need many more--and in a number of conditions, initial--high quality studies to assess the safety and efficacy of systemic glucocorticoid withdrawal schedules in chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12227130     DOI: 10.1016/s0889-8529(02)00008-7

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  17 in total

1.  Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment.

Authors:  Ombretta Viapiana; Davide Gatti; Sonila Troplini; Silvano Adami; Elena Fracassi; Luca Idolazzi; Maurizio Rossini
Journal:  Rheumatol Int       Date:  2014-08-23       Impact factor: 2.631

Review 2.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

Review 3.  Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Authors:  Hershel Raff; Susmeeta T Sharma; Lynnette K Nieman
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

4.  Steroids as pain relief adjuvants.

Authors:  Melissa Vyvey
Journal:  Can Fam Physician       Date:  2010-12       Impact factor: 3.275

5.  Dexamethasone prescribing for cancer pain between palliative care and radiation oncology.

Authors:  Andrew Jeong; Kevin Wade
Journal:  Support Care Cancer       Date:  2022-06-11       Impact factor: 3.359

Review 6.  Adrenal suppression from exogenous glucocorticoids: Recognizing risk factors and preventing morbidity.

Authors:  Alexandra Ahmet; Anne Rowan-Legg; Larry Pancer
Journal:  Paediatr Child Health       Date:  2021-06-11       Impact factor: 2.600

7.  Steroid management in newly diagnosed glioblastoma.

Authors:  Mariel B Deutsch; Katherine S Panageas; Andrew B Lassman; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

8.  Epimedium flavonoids counteract the side effects of glucocorticoids on hypothalamic-pituitary-adrenal axis.

Authors:  Jianhua Huang; Jijun Li; Songbai Zheng; Junzhen Wu; Wei Zhang; Tao Sun; Sheilesh Kumar Dewan; Bill Kalionis; Ziyin Shen; Xiantao Tai; Shijin Xia
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-23       Impact factor: 2.629

Review 9.  The role of corticosteroids in the treatment of pain in cancer patients.

Authors:  Wojciech Leppert; Tomasz Buss
Journal:  Curr Pain Headache Rep       Date:  2012-08

Review 10. 

Authors:  Alexandra Ahmet; Anne Rowan-Legg; Larry Pancer
Journal:  Paediatr Child Health       Date:  2021-06-11       Impact factor: 2.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.